Royalty Pharma (RPRX) Receivables - Other (2020 - 2023)
Royalty Pharma (RPRX) posted Receivables - Other of $14.2 million for Q4 2023, down 12.95% sequentially from $16.4 million in Q3 2023, and down 15.38% YoY from $16.8 million in Q4 2022.
Royalty Pharma (RPRX) Receivables - Other (2020 - 2023) Analysis & Trends
Royalty Pharma has reported Receivables - Other for 4 years, with the latest figure at $14.2 million in Q4 2023.
- Quarterly Receivables - Other fell 15.38% year-over-year to $14.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $14.2 million (down 15.38% YoY) and the FY2023 annual result came in at $14.2 million, down 15.38% from the prior year.
- Receivables - Other eased to $14.2 million in Q4 2023 per RPRX's latest filing, from $16.4 million in the prior quarter.
- Over five years, Receivables - Other peaked at $59.7 million in Q3 2021 and troughed at $14.2 million in Q4 2023.
- A 4-year average of $29.3 million and a median of $25.2 million in 2020 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2021 and 2022: Receivables - Other jumped 84.29% in 2021, then slumped 73.66% in 2022.
- Over 4 years, Receivables - Other stood at $32.4 million in 2020, then surged by 64.61% to $53.3 million in 2021, then sank by 68.42% to $16.8 million in 2022, then retreated by 15.38% to $14.2 million in 2023.
- According to Business Quant data, Receivables - Other over the past three periods registered $14.2 million, $16.4 million, and $16.4 million for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 14.24 Mn |
| Dec 31, 2023 | 14.24 Mn |
| Sep 30, 2023 | 16.36 Mn |
| Sep 30, 2023 | 16.36 Mn |
| Jun 30, 2023 | 16.36 Mn |
| Jun 30, 2023 | 16.36 Mn |
| Mar 31, 2023 | 16.36 Mn |
| Mar 31, 2023 | 16.36 Mn |
| Dec 31, 2022 | 16.83 Mn |
| Dec 31, 2022 | 16.83 Mn |
| Sep 30, 2022 | 15.71 Mn |
| Sep 30, 2022 | 15.71 Mn |
| Jun 30, 2022 | 18.03 Mn |
| Jun 30, 2022 | 18.03 Mn |
| Mar 31, 2022 | 51.19 Mn |
| Mar 31, 2022 | 51.19 Mn |
| Dec 31, 2021 | 53.29 Mn |
| Dec 31, 2021 | 53.29 Mn |
| Sep 30, 2021 | 59.66 Mn |
| Sep 30, 2021 | 59.66 Mn |